What Is Methadone and How Does It Work?

Methadone is a long-acting full opioid agonist that treats opioid use disorder, reducing craving and withdrawal through mu-opioid receptor binding and building cross-tolerance that blunts or blocks the effects of other opioids.

Per SAMHSA TIP 63, methadone is a Schedule II controlled medication. Its plasma half-life of 8 to 59 hours far exceeds its 4 to 8 hour duration of analgesia, and that single mismatch governs how clinicians prescribe it.

Key Takeaways

• Methadone acts as a full agonist at the mu-opioid receptor and as a noncompetitive antagonist at the NMDA receptor.
• Peak respiratory depression occurs later and persists longer than peak analgesia, particularly during initial dosing.
• Federal rules restrict methadone dispensing for opioid use disorder to certified opioid treatment programs and their medication units.
• Retention in methadone treatment cuts all-cause mortality roughly threefold and overdose mortality nearly fivefold against time out of treatment.
• Per TIP 63, arbitrary time limits on methadone treatment are medically unwarranted and inappropriate.

What Should You Do in an Opioid Emergency?

A suspected overdose requires 911 and naloxone given as quickly as possible, even when opioid involvement is uncertain. Per the FDA label, naloxone is safe to use even when opioids are not present.

Crisis resources. The 988 Suicide and Crisis Lifeline answers three ways: call 988, text 988, or chat at 988lifeline.org/chat. Spanish-language support answers by pressing 2, and the Lifeline’s videophone option serves ASL users.

Methadone’s pharmacology explains why the induction period carries the risk it does.

How Does Methadone Work in the Brain?

Methadone occupies the same mu-opioid receptors that heroin, fentanyl and prescription opioids act on, and methadone activates those receptors slowly. Slow activation produces cross-tolerance without the rapid onset that drives reinforcement.

Per StatPearls, methadone acts as a full agonist at the mu-opioid receptor and also as a noncompetitive antagonist at the N-methyl-D-aspartate receptor. That second action is unique among the opioid use disorder medications and contributes to methadone’s analgesic profile.

Per NIDA, methadone activates these receptors more slowly than heroin or fentanyl and remains in the body longer. Adequate dosing therefore blunts or blocks the effect of other opioids taken on top of methadone, which is the mechanism behind methadone’s protective effect against overdose. The half-life producing that protection also produces the main hazard.

Why Does Methadone’s Half-Life Matter So Much?

Methadone’s plasma elimination half-life of 8 to 59 hours outlasts its 4 to 8 hour duration of analgesic action, so a patient can feel a dose wearing off while the drug is still accumulating.

The FDA label states the clinical consequence directly: “The peak respiratory depressant effect of methadone occurs later, and persists longer than the peak analgesic effect, especially during the initial dosing period.” The same label notes that with repeated dosing methadone is retained in the liver and slowly released, prolonging the duration of potential toxicity.

Per TIP 63, the half-life averages 24 hours across patients while varying from 8 to 59 hours between them, and patients do not feel the full effect of an initial dose for 4 or more days even at an unchanged daily dose. Dose increases therefore run no more frequently than every 3 to 5 days per the FDA label, and some patients require up to 12 days between increases.

Federal rules cap the first day. Per 42 CFR Part 8, the total dose for the first day should not exceed 50 milligrams unless the practitioner documents a medical rationale for exceeding it. Where a patient collects that dose is also set in federal rule.

Where Can You Get Methadone for Opioid Use Disorder?

Federally certified opioid treatment programs are the only source of methadone for opioid use disorder in the United States. Per the FDA label, methadone for the treatment of opioid addiction shall be dispensed only by opioid treatment programs certified by SAMHSA and approved by the designated state authority, in oral form only.

A methadone prescription cannot be filled at a retail pharmacy the way a buprenorphine prescription can. One nuance matters: federal rules define a medication unit as a site geographically separate from an opioid treatment program from which community pharmacists may dispense medication on the program’s behalf. A pharmacist dispensing as part of an opioid treatment program is not the same as a prescription filled at any pharmacy.

The FDA label names two exceptions to program-only dispensing: inpatient care where the patient was admitted for a condition other than opioid addiction, and an emergency period of no longer than 3 days while definitive care is sought.

Current Take-Home Dose Limits

Federal rules set three tiers by time in treatment, and within each tier the number of doses remains at the practitioner’s discretion:

• Days 1 to 14: take-home supply limited to 7 days.
• From day 15: take-home supply limited to 14 days.
• From day 31: take-home supply not to exceed 28 days.

Separately, any patient in comprehensive treatment receives take-home doses for days the clinic closes, including one weekend day and state and federal holidays, regardless of time in treatment. Telehealth evaluation for a Schedule II medication such as methadone requires an audio-visual platform except where one is unavailable to the patient. The other agonist option carries different rules and a different risk profile.

How Does Methadone Compare With Buprenorphine?

Methadone retains more people in treatment and buprenorphine carries less overdose risk. Per Cochrane’s review of 24 randomized trials covering 4,497 participants, buprenorphine in flexible doses proved statistically significantly less effective than methadone at retaining patients, at a risk ratio of 0.80 with a 95 percent confidence interval of 0.68 to 0.95.

That same review found no difference in suppression of opioid use among those who stayed in treatment. Per NIDA, both medications prove equally effective at helping people reduce opioid use, and methadone keeps some people in treatment longer.

The safety difference runs the other way. Buprenorphine is a partial agonist with a ceiling effect on opioid activity, which per TIP 63 makes buprenorphine less likely than methadone and other full agonists to cause respiratory depression. Suboxone combines buprenorphine with naloxone.

Buprenorphine’s long receptor binding governs how long Suboxone stays in your system.

One thing the evidence does not support is a rule for matching patients to medications. TIP 63 states that no evidence clearly predicts which patients are best matched to buprenorphine versus other opioid use disorder medications. The practical differences are access, interactions and regulatory setting rather than clinical superiority. Three risks carry guideline-level weight.

What Are the Risks of Methadone?

Three methadone risks carry boxed-warning or guideline-level weight: respiratory depression during induction, QT interval prolongation, and the mortality spike on leaving treatment.

The FDA boxed warning records that QT interval prolongation and torsades de pointes have occurred during methadone treatment. Most reported cases involved patients treated for pain with large, multiple daily doses, and the label notes cases reported at doses commonly used for opioid use disorder maintenance. The label associates these cases more commonly with higher-dose treatment above 200 mg per day, while stating that the evidence strongly suggests methadone possesses the potential for adverse cardiac conduction effects in some patients. Per TIP 63, a QTc interval above 500 milliseconds raises the risk of this rare and potentially lethal arrhythmia, and clinicians do not start methadone in patients with a known QTc above 500 milliseconds.

Sordo and colleagues measured all-cause mortality dropping sharply over the first four weeks of methadone treatment, and identified the induction phase and the time immediately after leaving treatment as periods of particularly increased mortality risk. The accumulation problem described above is why induction stays supervised and titration stays slow.

Pregnancy carries its own standard of care. Per TIP 63, pregnant patients with opioid use disorder receive treatment with methadone or transmucosal buprenorphine, and research has shown that the dose of opioid agonist medication is not reliably related to the severity of neonatal abstinence syndrome. Per the FDA label, neonatal opioid withdrawal syndrome is an expected and treatable outcome of extended opioid use in pregnancy, and unlike opioid withdrawal in adults it may be life-threatening if not recognized and treated in the neonate. Those risks sit against a large mortality benefit.

How Well Does Methadone Actually Work?

Methadone treatment reduces all-cause mortality from 36.1 to 11.3 deaths per 1,000 person-years and overdose mortality from 12.7 to 2.6. Sordo and colleagues pooled 19 cohorts covering 122,885 people on methadone for up to 13.9 years.

Those figures give unadjusted out-to-in rate ratios of 3.20 for all-cause mortality, with a 95 percent confidence interval of 2.65 to 3.86, and 4.80 for overdose mortality, with an interval of 2.90 to 7.96.

Cochrane’s review of 11 randomized trials covering 1,969 participants found methadone statistically significantly more effective than non-pharmacological approaches at retaining patients and suppressing heroin use, at a risk ratio of 0.66 with an interval of 0.56 to 0.78. One precision point matters for anyone quoting these numbers: that same randomized set did not show a statistically significant mortality effect, so the mortality case rests on the cohort meta-analysis. How long treatment continues follows from those figures.

How Long Do People Stay on Methadone?

Methadone treatment continues for as long as it produces benefit, including indefinitely. Per TIP 63, longer lengths of stay in methadone treatment produce superior treatment outcomes, and leaving treatment raises the risk of death from overdose and other causes.

The TIP 63 expert panel considers arbitrary time limits on treatment to be medically unwarranted and inappropriate. Treatment runs short-term or long-term, including lifelong, and where tapering is chosen TIP 63 describes decreasing the dose gradually by 5 to 10 percent every 1 to 2 weeks. Patients taking medication for opioid use disorder count as being in recovery. Two beliefs about methadone cause more harm than any pharmacological risk.

Which Beliefs About Methadone Are Wrong?

Two widely held beliefs about methadone fail against the primary sources: that methadone substitutes one addiction for another, and that federal rules cap the first dose at 30 milligrams.

Common misconception	What the evidence shows
“Methadone just replaces one addiction with another.”	Per NIDA, methadone and buprenorphine prevent drug cravings and withdrawal symptoms without causing the intense feelings of pleasure that other opioid drugs produce, which makes them less addictive. NIDA concedes that both produce dependence and distinguishes dependence from addiction: withdrawal effects are milder than dependence on other opioids and are managed by reducing the dose slowly. NIDA has retired the term opioid substitution therapy for this reason.
“Federal rules cap the first methadone dose at 30 milligrams.”	That figure is the pre-2024 rule and still appears in older guidance. Current federal rule at 42 CFR Part 8 provides that the total dose for the first day should not exceed 50 milligrams unless the practitioner documents a medical rationale for a higher dose.

Methadone maintenance prevents the opioid withdrawal symptoms that otherwise begin 8 to 24 hours after the last short-acting dose.

Where Can You Get Opioid Use Disorder Treatment in Los Angeles?

New Spirit Recovery provides medication-assisted treatment at its Encino location, using buprenorphine and naltrexone with an on-site psychiatric provider setting the regimen. Methadone for opioid use disorder is dispensed only through certified opioid treatment programs.

Clinicians coordinate care with a licensed program where methadone fits the patient better. Medication-assisted treatment runs alongside detox and counseling.

The admissions intake determines which medication fits the patient.

“Coordinating care with an opioid treatment program is a daily logistical reality for the patient, not a detail. Nursing staff work alongside the medical providers to keep that continuity intact, because a missed day is a clinical event rather than an administrative one.” Cynthia Prieto, LVN, Director of Nursing at New Spirit Recovery.

Frequently Asked Questions

What is methadone used for?

Methadone treats opioid use disorder and, separately, severe pain. For opioid use disorder methadone reduces craving and withdrawal through mu-opioid receptor binding and cross-tolerance, blunting or blocking the effects of other opioids at adequate doses.

How long does methadone stay in your system?

Per the FDA label, methadone’s plasma elimination half-life ranges from 8 to 59 hours, averaging around 24 hours. Its analgesic effect lasts only 4 to 8 hours, so the drug remains in the body well after the dose stops being felt.

Can you get methadone from a pharmacy?

Not as an ordinary prescription. Methadone for opioid use disorder is dispensed only by federally certified opioid treatment programs. A community pharmacist can dispense methadone as part of a program’s medication unit, which is not the same as filling a prescription at any pharmacy.

Is methadone better than Suboxone?

Neither medication is better overall. Methadone retains more people in treatment, at a risk ratio of 0.80 for buprenorphine against methadone across 24 trials. Buprenorphine’s partial agonism gives it a ceiling effect lowering respiratory depression risk. TIP 63 states that no evidence predicts which patient suits which medication.

Does methadone reduce the risk of dying?

Yes, substantially. Across 19 cohorts covering 122,885 people, all-cause mortality ran 11.3 per 1,000 person-years in methadone treatment against 36.1 out of it, and overdose mortality 2.6 against 12.7.

How much methadone is given on the first day?

Federal rules cap the first day at 50 milligrams total unless the practitioner documents a medical rationale for exceeding it. Dose increases then run no more frequently than every 3 to 5 days, and some patients need up to 12 days between increases.

References

1. US Food and Drug Administration. Methadone Hydrochloride Tablets: Prescribing Information. DailyMed, National Library of Medicine.
2. Substance Abuse and Mental Health Services Administration. (2021). Medications for Opioid Use Disorder. Treatment Improvement Protocol (TIP) Series, No. 63.
3. Certification of Opioid Treatment Programs, 42 CFR Part 8.
4. Sordo, L., et al. (2017). Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ, 357, j1550.
5. Mattick, R. P., Breen, C., Kimber, J., Davoli, M. (2008; 2009). Buprenorphine maintenance versus placebo or methadone maintenance; and Methadone maintenance therapy versus no opioid replacement therapy. Cochrane Database of Systematic Reviews.
6. National Institute on Drug Abuse. Medications for Opioid Use Disorder; and Words Matter: Terms to Use and Avoid When Talking About Addiction.
7. Durrani, M., Bansal, K. Methadone. StatPearls. National Library of Medicine.